DJ Johnson & Johnson Seeks Emergency Authorization for Covid Vaccine. The Stock Moved Higher. -- Barrons.com
Johnson & Johnson said Thursday it submitted its vaccine to the U.S. Food and Drug Administration for an emergency use authorization.
The company (ticker: JNJ) said it plans to distribute the vaccine to the U.S. government following authorization. It expects to supply 100 million doses to the U.S. in the first half of the year. Paul Stoffels, the company's chief scientist, said in a news release that the company is prepared to begin shipping upon authorization.
"With our submission to the FDA and our ongoing reviews with other health authorities around the world, we are working with great urgency to make our investigational vaccine available to the public as quickly as possible," he added.
Last week, the company said its single-dose vaccine was 66% effective in preventing moderate to severe Covid-19. A Phase 3 trial of more than 43,000 participants showed it was 85% effective at preventing severe disease. It also prevented hospitalization and death from Covid-19 completely at 28 days following vaccination. The 85% effective rate was consistent even in South Africa, where a new strain of Covid-19 has worried experts.
The company says its vaccine is estimated to remain stable for two years at negative four degrees Fahrenheit, at least three months of which can be stored in standard refrigerators between 36 degrees and 46 degrees Fahrenheit.
The stock (ticker: JNJ) ticked 2% higher in after-hours trading following the announcement. Johnson & Johnson shares have gained about 5.5% in the past year.
Write to Connor Smith at email@example.com
(END) Dow Jones Newswires
February 04, 2021 19:04 ET (00:04 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.